The Enterprise Value as of June 2026 (TTM) for Monopar Therapeutics Inc. (MNPR) is 347.99M

According to Monopar Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 347.99M. This represents a change of -4.38% compared to the average of 363.93M of the last 4 quarters.

Monopar Therapeutics Inc. (MNPR) Historical Enterprise Value (quarterly & annually)

How has MNPR Enterprise Value performed in the past?

The mean historical Enterprise Value of Monopar Therapeutics Inc. over the last ten years is 620.16M. The current 347.99M Enterprise Value has changed 5.51% with respect to the historical average. Over the past ten years (40 quarters), MNPR's Enterprise Value was at its highest in in the March 2017 quarter at 1.38B. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.

Monopar Therapeutics Inc. (MNPR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Monopar Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Monopar Therapeutics Inc. (MNPR) Average Enterprise Value

How has MNPR Enterprise Value performed in the past?

The current Enterprise Value of Monopar Therapeutics Inc. (MNPR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Monopar Therapeutics Inc. (MNPR) Enterprise Value vs. Peers

How is MNPR’s Enterprise Value compared to its peers?

Monopar Therapeutics Inc.’s Enterprise Value is greater than Compass Therapeutics, Inc. (235.34M), less than 4D Molecular Therapeutics, Inc. (409.65M), greater than Bicycle Therapeutics plc (-264552133.00), greater than Fulcrum Therapeutics, Inc. (142.29M), greater than Gossamer Bio, Inc. (199.90M), less than Lexicon Pharmaceuticals, Inc. (872.47M), less than Omeros Corporation (940.92M), less than KalVista Pharmaceuticals, Inc. (1.49B), greater than Akebia Therapeutics, Inc. (97.86M), greater than Neumora Therapeutics, Inc. Common Stock (183.14M),

Build a custom stock screener for Monopar Therapeutics Inc. (MNPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monopar Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monopar Therapeutics Inc. (MNPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monopar Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.